BBIO
Price
$50.05
Change
+$1.05 (+2.14%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
9.37B
34 days until earnings call
XENE
Price
$37.98
Change
+$1.46 (+4.00%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
2.82B
40 days until earnings call
Interact to see
Advertisement

BBIO vs XENE

Header iconBBIO vs XENE Comparison
Open Charts BBIO vs XENEBanner chart's image
BridgeBio Pharma
Price$50.05
Change+$1.05 (+2.14%)
Volume$28.64K
Capitalization9.37B
Xenon Pharmaceuticals
Price$37.98
Change+$1.46 (+4.00%)
Volume$12.06K
Capitalization2.82B
BBIO vs XENE Comparison Chart in %
Loading...
BBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BBIO vs. XENE commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BBIO is a StrongBuy and XENE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (BBIO: $50.05 vs. XENE: $37.98)
Brand notoriety: BBIO and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BBIO: 26% vs. XENE: 31%
Market capitalization -- BBIO: $9.37B vs. XENE: $2.82B
BBIO [@Biotechnology] is valued at $9.37B. XENE’s [@Biotechnology] market capitalization is $2.82B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BBIO’s FA Score shows that 1 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • BBIO’s FA Score: 1 green, 4 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, XENE is a better buy in the long-term than BBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BBIO’s TA Score shows that 4 TA indicator(s) are bullish while XENE’s TA Score has 5 bullish TA indicator(s).

  • BBIO’s TA Score: 4 bullish, 4 bearish.
  • XENE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, XENE is a better buy in the short-term than BBIO.

Price Growth

BBIO (@Biotechnology) experienced а -4.43% price change this week, while XENE (@Biotechnology) price change was +2.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.14%. For the same industry, the average monthly price growth was +9.25%, and the average quarterly price growth was +54.64%.

Reported Earning Dates

BBIO is expected to report earnings on Oct 30, 2025.

XENE is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+4.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BBIO($9.37B) has a higher market cap than XENE($2.82B). BBIO YTD gains are higher at: 78.571 vs. XENE (-3.112). XENE has higher annual earnings (EBITDA): -315.5M vs. BBIO (-643.59M). BBIO has more cash in the bank: 757M vs. XENE (488M). XENE has less debt than BBIO: XENE (8.72M) vs BBIO (1.86B). BBIO has higher revenues than XENE: BBIO (236M) vs XENE (7.5M).
BBIOXENEBBIO / XENE
Capitalization9.37B2.82B333%
EBITDA-643.59M-315.5M204%
Gain YTD78.571-3.112-2,525%
P/E RatioN/AN/A-
Revenue236M7.5M3,147%
Total Cash757M488M155%
Total Debt1.86B8.72M21,320%
FUNDAMENTALS RATINGS
BBIO vs XENE: Fundamental Ratings
BBIO
XENE
OUTLOOK RATING
1..100
5761
VALUATION
overvalued / fair valued / undervalued
1..100
4
Undervalued
74
Overvalued
PROFIT vs RISK RATING
1..100
7640
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
4055
P/E GROWTH RATING
1..100
1006
SEASONALITY SCORE
1..100
n/a90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BBIO's Valuation (4) in the null industry is significantly better than the same rating for XENE (74) in the Biotechnology industry. This means that BBIO’s stock grew significantly faster than XENE’s over the last 12 months.

XENE's Profit vs Risk Rating (40) in the Biotechnology industry is somewhat better than the same rating for BBIO (76) in the null industry. This means that XENE’s stock grew somewhat faster than BBIO’s over the last 12 months.

XENE's SMR Rating (97) in the Biotechnology industry is in the same range as BBIO (100) in the null industry. This means that XENE’s stock grew similarly to BBIO’s over the last 12 months.

BBIO's Price Growth Rating (40) in the null industry is in the same range as XENE (55) in the Biotechnology industry. This means that BBIO’s stock grew similarly to XENE’s over the last 12 months.

XENE's P/E Growth Rating (6) in the Biotechnology industry is significantly better than the same rating for BBIO (100) in the null industry. This means that XENE’s stock grew significantly faster than BBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BBIOXENE
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
68%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
76%
MACD
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
73%
Advances
ODDS (%)
Bullish Trend 11 days ago
79%
Bullish Trend 9 days ago
73%
Declines
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
71%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
BBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FFEIX15.25N/A
N/A
Nuveen Dividend Value A
IAMOX3.44N/A
N/A
Voya MidCap Opportunities Port A
MISGX13.02N/A
N/A
Meridian Small Cap Growth Investor
RGBLX40.60N/A
N/A
American Funds Global Balanced R1
TSPFX5.91N/A
N/A
Transamerica Small Cap Growth R4

BBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, BBIO has been loosely correlated with XENE. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if BBIO jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BBIO
1D Price
Change %
BBIO100%
-3.26%
XENE - BBIO
44%
Loosely correlated
-0.19%
IRON - BBIO
43%
Loosely correlated
+0.18%
RLAY - BBIO
41%
Loosely correlated
-3.10%
ALNY - BBIO
41%
Loosely correlated
-1.92%
ROIV - BBIO
41%
Loosely correlated
+1.77%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with NUVL. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
+4.00%
NUVL - XENE
60%
Loosely correlated
+4.99%
IDYA - XENE
56%
Loosely correlated
+4.52%
CRNX - XENE
54%
Loosely correlated
+27.92%
IMVT - XENE
52%
Loosely correlated
+3.51%
NRIX - XENE
51%
Loosely correlated
+7.20%
More